Irritable Bowel Syndrome Treatment Market is Expected to Reach a Market Value of US$ 9,355.4 Million by the End of 2034 | Fact.MR Study

The global market for irritable bowel syndrome treatment was approximately US$ 2,744.9 million in 2019. After the year 2019, some private companies have emerged with advanced and effective solutions for irritable bowel syndrome as well as inflammatory bowel disease.

The increasing incidence of irritable bowel syndrome (IBS) is the major driving force behind the demand for IBS medication programs and IBS natural remedies. In 2024, the net value of revenue generated by adopting irritable bowel syndrome treatment products and services will be approximately US$ 4,076.1 million.

The requirement for effective IBS therapy, and IBS counseling services, is likely to rise with the growing incidence of irritable bowel syndrome. As per Fact.MR's analysis on market trends, irritable bowel syndrome treatment demand is anticipated to advance at a CAGR of 8.7% during the period from 2024 to 2034. Following this profitable growth rate, the total value of the business is anticipated to rise up to US$ 9,355.4 million by the end of 2034.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9520

Key Takeaways from Market Study:

The estimated market value for the irritable bowel syndrome (IBS) treatment market in 2024 is projected to reach US$ 4,076.1 million, reflecting the rising awareness and demand for effective treatment options for IBS.
By 2034, the market is forecasted to expand to US$ 9,355.4 million, driven by advancements in treatment therapies and increasing prevalence of IBS worldwide.
The global market is expected to grow at a robust CAGR of 8.7% from 2024 to 2034, indicating the growing need for IBS treatments as more people are diagnosed with the condition.
The fiber supplements segment is projected to experience a growth rate of 9.6% CAGR during the forecast period, fueled by their effectiveness in managing IBS symptoms and the increasing preference for natural treatment options.
The irritable bowel syndrome with diarrhea (IBS-D) segment is expected to grow at a higher rate of 10.3% CAGR, driven by the rising incidence of this subtype of IBS and the development of targeted therapies.
The retail pharmacies segment is set to grow at a rate of 9.4% CAGR from 2024 to 2034, supported by the increasing number of consumers seeking accessible IBS treatments through pharmacies.
North America is projected to hold a market share of 8.8% in 2024, owing to advanced healthcare systems, a high prevalence of IBS, and the availability of cutting-edge treatment options.
East Asia is expected to contribute a market share of 7.3% in 2024, driven by growing healthcare awareness and increasing healthcare infrastructure in the region.

Leading Players Driving Innovation in the Irritable Bowel Syndrome Treatment Market:

Takeda Pharmaceutical Company Limited; Pfizer, Inc.; Abbott Laboratories; Novartis AG; AstraZeneca PLC; Ironwood Pharmaceuticals Inc. and Allergan Plc; Bausch Health Companies Inc.; GlaxoSmithKline, Plc.; Lexicon Pharmaceuticals, Inc.; Sucampo Pharmaceuticals, Inc.

Country-wise Insights:

Market revenue earned in the North America irritable bowel syndrome (IBS) treatment market is approximated at US$ 1,722 million in 2024. Individualized IBS treatment services are leading the North American market since patient-oriented care patterns are more sought after in the United States and Canada.

The United States contributes close to 89.2% of the North American market share, and the net value of this regional market is approximated to be in the region of US$ 1,536 million in the year 2024. Market players in the United States consider the needs, wants, and lifestyle factors of individual patients, focusing on patient-centricity and holism.

For example, Ardelyx, an American biopharmaceutical company, gained approval of IBSRELA, which is a tenapanor-based drug employed to treat irritable bowel syndrome, in 2021.

The uptake of irritable bowel syndrome treatment services across Mexico is increasing at a higher pace, and the local market is expected to grow at a CAGR of 8.9% until 2034, ending at a value of US$ 92 million. In contrast, the Canadian irritable bowel syndrome market is expected to register an 8.7% year-on-year growth rate and end up at a value of 339 million in 2034.

Browse Full Report: https://www.factmr.com/report/irritable-bowel-syndrome-treatment-market

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the global irritable bowel syndrome treatment market, presenting historical data for 2019 to 2023 and forecast statistics for 2024 to 2034.

The irritable bowel syndrome (IBS) treatment industry is segmented based on product type, indication, distribution channel, and region. In terms of product type, the market includes a variety of treatments such as Fiber Supplements, Anti-Diarrheal medications, Anticholinergic and Antispasmodic drugs, Antidepressants, Antibiotics, Alosetron, Lubiprostone, Linaclotide, and NHE3 inhibitors, each addressing different symptoms and underlying causes of IBS. The market is also segmented by indication, with treatments tailored for Irritable Bowel Syndrome with Constipation, Irritable Bowel Syndrome with Diarrhea, and Irritable Bowel Syndrome with Alternating Constipation and Diarrhea.

Distribution channels for IBS treatments include Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Stores, Hypermarkets and Supermarkets, as well as other alternative distribution methods. Regionally, the market spans across North America, Europe, Latin America, East Asia, South Asia & Oceania, and the Middle East & Africa (MEA), with varying demands and growth prospects in each region depending on healthcare infrastructure, diagnosis rates, and treatment accessibility.

Check out More Related Studies Published by Fact.MR:

Chronic Idiopathic Constipation Treatment Market - https://www.factmr.com/report/chronic-idiopathic-constipation-treatment-market

Endoscopy Procedures Estimates Market - https://www.factmr.com/report/endoscopy-procedures-estimates-market

Ulcerative Colitis Therapeutics Market - https://www.factmr.com/report/ulcerative-colitis-therapeutics-market

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

This release was published on openPR.